Mazdutide

Mazdutide is a dual glucagon and GLP-1 receptor agonist in development for obesity; community use centers on appetite suppression and weight loss, with three-quarters of the small captured cohort rating outcomes positively. Users most often report 2 mg daily inside a 1–3 mg band, while one clinician-facing source lists 3 mg subcutaneously on a weekly schedule. The tradeoff is that off-label discussion and exploratory trials outpace the real-world evidence base, which rests on only eight captured community reports and largely unposted results.

Mazdutide

Research Evidence

Evidence shape

Mazdutide holds moderate evidence weight: the strongest trials center on obesity, the sole indication with posted results, with six trials reporting a +6.5 percent change. Across 20 mapped indications, eighteen are thin or exploratory and fifteen rest on a single trial, backed by only one blinded result and two distinct sponsors. Of 32 registered trials, 16 are completed but just one has posted results, leaving most indications beyond obesity still exploratory.

Depthhow much
32 registered trials
16 completed · 1 with posted results · 16 recruiting / active · combined n=179
Breadthhow many areas
20 indications mapped
1 with results · 18 thin / exploratory · 1 animal-only · 15 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
1 blinded with results · 2 distinct sponsors · AE table from NCT06124807 · 8 linked publications on registered trials
Breadth and depth33 rows captured
Human
direct clinical signal
32
Animal
translational support
1
In vitro
mechanistic support
0
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Anecdotal side effects

Price

1
Prism Aminos
US
10 mg
$35.50
$3.55/mg
2
Stackhaus Research
--
10 mg
$49.00
$4.9/mg
3
Eros Peptides
US
10 mg
$55.99
$5.6/mg
4
Edge Peptides
CN
50 mg
$300.00
$6/mg
5
Nextday Peptides
--
100 mg
$693.85
$6.94/mg
6
Peakformpeptides
US
10 mg
$75.00
$7.5/mg

price offers can be sorted by column

1-6 of 16

Dosing & Protocol

How Mazdutide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 16
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

16 completed trials identified; trial dosing not reliably extracted from registry data.

8 sources
Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
3 mg
3 mg
3 mg
Frequency
weekly
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 3 mg weekly subQ (1 source).

1 source
Anecdotal
Community-reported real-world use · n = 5
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Community reports, primarily for weight loss and appetite suppression, indicate positive outcomes in 80% of 5 reports, with 20% mixed. Specific dosing information is not consistently reported in anecdotal submissions.

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for Mazdutide, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.